Zepbound and Mounjaro are both injectable GLP-1/GIP prescription medications with the same active ingredient, tirzepatide. Although they are practically considered the same drug, Zepbound and Mounjaro are FDA-approved for different purposes.
Zepbound is a prescription medication that was approved by the FDA in 2022 for adults with obesity or a weight-related condition, including type 2 diabetes and high blood pressure. Mounjaro, with the same effects on the body, was also approved in 2022, but for improving glycemic control in individuals with type 2 diabetes.
In this article, you will learn about the similarities and differences between Zepbound and Mounjaro, including their side effects, recommended doses, and ways to save on your next prescription.
Disclaimer: This article is for informational purposes only and is not medical advice. Always consult your doctor or diabetes care team before making changes to your treatment plan.
Quick Facts
- Same active ingredient: Both Zepbound and Mounjaro contain tirzepatide, a dual GIP/GLP-1 receptor agonist.
- Different indications: Zepbound is approved for chronic weight management, while Mounjaro is approved for type 2 diabetes management.
- Different dosing goals: Zepbound doses aim for weight loss outcomes (up to 15 mg weekly), while Mounjaro dosing is tailored to blood sugar control and metabolic needs (up to 15 mg weekly).
- Not interchangeable: Even though they use the same medication, Zepbound and Mounjaro should not be substituted for each other without medical supervision due to different approved uses.
- Side effects: Both can cause similar side effects, including nausea, vomiting, diarrhea, constipation, and injection site reactions.
Overview of Each Product
Mounjar and Zepbound are names for the drug tirzepatide. It is a medication approved by the FDA for treating type 2 diabetes and has also been found to be effective in managing weight.
Tirzepatide is a dual agonist for the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. GLP-1 and GIP mimic the effects of two gut hormones that are released after consuming food.
When administered, they promote the release of insulin to control blood sugar levels and keep the patient satiated for a longer period.
Zepbound – Mechanism, Indications, Key Traits
Zepbound Pens
$499.99Zepbound is an injectable GLP-1/GIP prescription medication approved by the FDA for chronic weight management. It is prescribed to adults with obesity (with a BMI of 30+), overweight (with a BMI of 27+), or with at least one weight-related condition.
Zepbound was also approved to treat moderate-to-severe obstructive sleep apnea in obese or overweight adults in 2024.
Unlike Ozempic or Wegovy, Zepbound mimics two gut hormones (GLP-1 and GIP) that regulate blood sugar, stimulate insulin production, and slow down the rate at which food leaves the stomach.
- Formulation: Available as a once-weekly subcutaneous injection. In Canada, Zepbound pens are multi-dose KwikPens that deliver four weekly doses per pen.
- Indications: A dual GIP and GLP-1 receptor agonist indicated for chronic weight management in adults with obesity or overweight with at least one weight-related condition.
- Key traits: Non-insulin injectable medication that helps reduce appetite, slow digestion, and promote a feeling of fullness.
Mounjaro – Mechanism, Indications, Key Traits
Mounjaro KwikPens
$499.99Mounjaro is also an injectable medication approved by the FDA to improve glycemic control in adults and children 10 years of age and older with type 2 diabetes. Same as Zepbound, Mounjaro is a dual GIP and GLP-1 receptor agonist that regulates blood sugar levels and promotes insulin production.
Mounjaro may be prescribed for its off-label effects on weight management, but the recommended dosages of the two tirzepatide medications are slightly different.
- Formulation: Available as a once-weekly subcutaneous injection in prefilled single-dose pens.
- Indications: A dual GIP and GLP-1 receptor agonist used together with diet and exercise to improve glycemic (blood sugar) control in adults with type 2 diabetes.
- Key traits: Non-insulin injectable medication that targets both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors.
Zepbound vs. Mounjaro: Side-by-Side Comparison
| Feature | Zepbound | Mounjaro |
|---|---|---|
| Mechanism | Dual GIP & GLP-1 receptor agonist (tirzepatide) | Dual GIP & GLP-1 receptor agonist (tirzepatide) |
| Dosing | Once weekly, via pen only | Once weekly, via pens or vials |
| Efficacy | Proven for significant long-term weight loss with diet and exercise | Proven to improve blood glucose control; also supports weight loss when used with lifestyle changes |
| Onset & Duration | Onset: within hours, lasts ~24 hours | Onset: within hours, lasts ~24 hours |
| Side effects | Nausea, diarrhea, vomiting, constipation, decreased appetite | Nausea, diarrhea, low appetite, vomiting, indigestion, constipation |
| Cost | High; typically ~$1,000+ per month without insurance | High; typically ~$1,000–$1,200 per month without insurance |
| Approval status | FDA-approved for chronic weight management (obesity/overweight) | FDA-approved for type 2 diabetes |
| Limitations | Should not be used with other GLP-1 agonists or other tirzepatide products | Not approved for weight loss specifically (weight loss is secondary) |
Zepbound vs. Mounjaro: Differences & Similarities Explained
Similarities
When comparing Zepbound vs. Mounjaro, there are several key similarities, including:
- Contain tirzepatide, a dual GIP & GLP-1 receptor agonist
- Work by reducing appetite, slowing gastric emptying, and improving metabolic and insulin response
- Begin working within hours, with effects maintained through once-weekly dosing
- Administered once daily as a subcutaneous injection (stomach, thigh, or upper arm)
- Delivered using a prefilled, multi-dose injection pen
Differences
Although Zepbound and Mounjaro contain the same active ingredient (tirzepatide), they differ in important ways:
- Uses
- Zepbound: Approved for chronic weight management and for moderate to severe obstructive sleep apnea (OSA) in adults with obesity.
- Mounjaro: Approved for type 2 diabetes management to improve blood sugar control.
- Dosage: Both medications are administered subcutaneously once weekly, but recommended starting points and intended treatment goals differ:
- Zepbound: Given in 2.5 mg once weekly and gradually increased up to 15 mg for weight-management goals.
- Mounjaro: Given in 2.5 mg once weekly, gradually increased to a range of 5 mg to 15 mg, depending on glycemic response and the individual treatment plan.
- Insurance coverage: Coverage for Zepbound is often limited or variable for weight-management medications, while Mounjaro is commonly covered under diabetes treatment benefits.
- Cost: Zepbound and Mounjaro cost similarly without insurance, and both may have savings programs available to eligible patients.
Clinical Trials
Zepbound
Clinical trials show that Zepbound (tirzepatide) has been extensively studied for weight management and obesity treatment.
Its primary evidence comes from the SURMOUNT-1 trial, a large 72-week, randomized, double-blind, placebo-controlled study involving more than 2,500 adults with obesity or overweight and at least one weight-related condition (but without diabetes).
Across the trial, patients receiving Zepbound achieved an average reduction in body weight of 15% to 21%, depending on the dose, compared with approximately 3% in the placebo group.
Many patients achieved deeper weight loss, with nearly 60% of participants on the highest dose (15 mg) losing 20% or more of their body weight.
Beyond weight reduction, Zepbound patients also experienced improvements in waist circumference, blood pressure, lipid levels, and markers of metabolic health. Positive results were consistent across additional SURMOUNT trials, supporting Zepbound’s role in long-term obesity management when paired with nutrition and physical activity guidance.
Mounjaro
Clinical evidence confirms that Mounjaro (tirzepatide) is effective for improving blood sugar control in adults with type 2 diabetes, based on extensive research including the Phase 3 SURPASS clinical trial program.
According to a 2023 endocrine review published in the Journal of Diabetes, Obesity and Metabolism, tirzepatide is approved in the U.S. to improve glycemic control and is being further studied for weight management and cardiovascular outcomes.
Across SURPASS-1 to SURPASS-5, tirzepatide delivered significant HbA1c reductions of −1.87% to −2.59%, with a majority of patients reaching ADA treatment goals (HbA1c <7%). Participants also experienced significant reductions in body weight (−6.2 to −12.9 kg) and improvements in markers of cardiovascular and metabolic health, including blood pressure, visceral adiposity, and triglycerides.
In head-to-head comparisons, tirzepatide outperformed established treatments such as semaglutide 1 mg (SURPASS-2) and basal insulins like degludec and glargine (SURPASS-3 and SURPASS-4), highlighting its strength among current type 2 diabetes therapies.
Safety findings show a low risk of hypoglycemia when not combined with insulin or sulfonylureas, and a tolerability profile similar to the GLP-1 receptor agonist class.
Mounjaro vs. Zepbound: Use Cases & Which Is Better for You
When to Choose Mounjaro
- If you have type 2 diabetes and need stronger blood sugar control.
- If your primary goal is lowering A1C, with weight loss as a supportive benefit.
- If you want a non-insulin injection that can be used alongside other diabetes medications.
- If you have tried oral medications but need additional metabolic support.
When to Choose Zepbound
- If your main goal is weight loss or long-term weight management.
- If you meet medical criteria for treatment (e.g., BMI ≥30, or BMI ≥27 with weight-related conditions).
- If you do not need diabetes treatment, or diabetes management is not the priority.
- If you want an injectable that reduces appetite, cravings, and overeating triggers.
- If dieting, calorie tracking, or lifestyle changes alone haven’t delivered sustainable weight loss.
Special Populations
- Zepbound and Mounjaro are not recommended if you are allergic to tirzepatide or any ingredients in the medication.
- Patients with kidney or liver issues should consult their healthcare provider first, as additional monitoring may be necessary.
- Those with a history of pancreatitis, thyroid cancer (MTC), or MEN 2 should discuss risks carefully with a clinician due to the boxed warning associated with these conditions.
Zepbound vs. Mounjaro: Risks, Side Effects & Warnings
When using Zepbound or Mounjaro, you may experience similar side effects since both medications contain tirzepatide. The most common issues are gastrointestinal and may include nausea, vomiting, diarrhea, constipation, or decreased appetite as the body adjusts to treatment.
Other common adverse effects include fatigue, indigestion, acid reflux, and injection-site soreness.
Serious side effects are less common but require urgent medical attention if they occur. These include signs of pancreatitis (severe stomach pain that may spread to the back), gallbladder problems, severe allergic reactions, or sudden changes such as difficulty swallowing, hoarseness, or swelling in the neck, which could signal thyroid-related concerns.
Monitoring Requirements
Patients using Zepbound or Mounjaro should be monitored regularly by a healthcare provider.
Monitoring may include tracking blood glucose (especially for those with type 2 diabetes), body weight, and response to treatment, gastrointestinal tolerance as doses increase, and symptoms that may indicate pancreatitis, gallbladder disease, or thyroid-related concerns.
Warnings
Zepbound and Mounjaro should not be used together, as they contain the same active ingredient (tirzepatide). Switching between the two should only be done under medical supervision, since they are approved for different indications (weight management vs. type 2 diabetes).
Drug Interactions
Zepbound and Mounjaro may interact with medications that affect blood sugar or gastric emptying. The following treatments may require closer monitoring or dose adjustments:
- Insulin or insulin-stimulating medications, which may increase the risk of hypoglycemia
- Other incretin-based therapies (GLP-1 receptor agonists, DPP-4 inhibitors)
- Oral medications that require rapid absorption, due to delayed gastric emptying with tirzepatide
Zepbound vs. Mounjaro: Cost & Coverage
Zepbound Pens
$499.99Mounjaro KwikPens
$499.99If you compare the Zepbound pens to the Mounjaro pens, one of the first differences you’ll notice is the cost in the US and Canada.
| Zepbound | Mounjaro | |
|---|---|---|
| Average Price in the U.S pharmacy | Starts at ~$1,000 | Starts at ~$1,000–$1,200 |
| Price at Insulin Outlet | $559.99 per pack (Zepbound KwikPen) | $559.99 (Mounjaro KwikPen) |
Zepbound is a slightly cheaper option, but the cost of either of the medications may be reduced in other ways:
| Zepbound | Mounjaro | |
|---|---|---|
| Insurance Coverage | Often not covered or restricted; most insurance plans classify it as a weight-loss medication | More likely to be covered by insurance when prescribed for its FDA-approved diabetes indication |
For patients without insurance, there are a few ways to reduce the expense:
| Financial assistance | Zepbound | Mounjaro |
|---|---|---|
| GoodRx discounts | Some pharmacies might offer Zepbound or Mounjaro at lower prices, but availability varies, and discounts may be temporary. | |
| Savings Cards* | Pay as low as $25 for a 1-month or 3-month prescription with the Zepbound Savings Card. | Pay as low as $25 for a prescription up to 3 months with the Mounjaro Savings Card. |
*Not available for patients with any state, federal, or government-funded healthcare programs
Save on Zepbound and Mounjaro with Insulin Outlet
One of the most effective ways to reduce the cost of Zepbound or Mounjaro is by ordering from Canada. Prices in Canada are often significantly lower than in the U.S., and medications remain fully regulated and authentic.
Insulin Outlet connects U.S. patients with reputable Canadian pharmacies, offering secure access to prescription medications at more affordable prices and without compromising on quality or safety.
✔️ Fast processing, with most orders confirmed within one business day
✔️ Convenient online ordering with direct home delivery
✔️ User-friendly platform plus exclusive member discounts
✔️ Real savings on genuine Zepbound and Mounjaro sourced from Canada
✔️ 10% off your first order with code WELCOME10
Here is how much you can save:
Simply place your order for Zepbound or Mounjaro, submit your prescription, and get your medication shipped to your home within about 10 days.
Frequently Asked Questions
Are Zepbound and Mounjaro interchangeable?
No. Although both contain tirzepatide, they are approved for different uses and have different coverage pathways. Any switch between them should be supervised by a healthcare provider to ensure appropriate dosing and treatment goals.
Which one leads to more weight loss?
Zepbound is FDA-approved specifically for weight management and is prescribed at doses intended for weight reduction. Mounjaro may support weight loss as a secondary benefit, but it is primarily prescribed for blood sugar control in type 2 diabetes.
How is dosing different between Zepbound and Mounjaro?
Both medications follow a weekly injection schedule, but doses are titrated based on treatment goals. Zepbound is typically increased for weight management results, while Mounjaro titration focuses on improving A1C and glucose control.
Do Zepbound and Mounjaro cost the same?
No. Zepbound is often more difficult to insure because it is classified as a weight-loss medication, making out-of-pocket costs higher. Mounjaro is more likely to be covered under diabetes drug benefits and may qualify for savings programs, depending on insurance.
Do Zepbound and Mounjaro have different side effects?
Side effects are generally similar because both medications contain tirzepatide. Nausea, vomiting, diarrhea, and decreased appetite are common during dose increases. Serious risks such as pancreatitis or thyroid-related concerns are rare but possible and require prompt medical attention.
Conclusion & Next Steps
Zepbound and Mounjaro both contain the same active ingredient, tirzepatide, and share similar mechanisms of action. However, they are approved for different uses.
Zepbound is specifically indicated for chronic weight management, whereas Mounjaro is primarily prescribed to improve blood sugar control in adults with type 2 diabetes, with weight loss as an additional benefit. Their dosing goals, insurance coverage, and cost implications also differ based on indication and plan coverage.
Choosing between Zepbound and Mounjaro depends on your individual health needs and treatment objectives. It’s essential to consult your healthcare provider to determine which option is most suitable for your specific situation.
If you already have a prescription for Zepbound or Mounjaro, Insulin Outlet provides a trusted way to access authentic medications at lower prices through Canadian pharmacies, helping you save while staying consistent with your treatment plan.
Disclaimer: This article is for informational purposes only and is not medical advice. Always consult your doctor or diabetes care team before making changes to your treatment plan.
Share:
